A new study commissioned by Dynavox Group demonstrated that the use of high-tech augmentative and alternative communication (AAC) can enormously impact the functionality and quality of life for both the AAC users and their caregivers. “Exploring the Benefits of Assistive Communication” was described as a health economic study conducted in the United States by Augur…
Study: High-Tech AAC Dramatically Improves Outcomes for Users with CP, ALS
Scott-Morgan Foundation, Lenovo Introduce AI-Powered Communication Tech for People with ALS
New system gives people with ALS greater ability to personalize their communications, today and going forward.
New technology powered by artificial intelligence (AI) could offer greater communications customizability for people with conditions such as amyotrophic lateral sclerosis (ALS). In an October press release, the Scott-Morgan Foundation and Lenovo introduced “a new technology suite combining predictive AI, hyper-realistic avatars, personalized voices, and eye-gaze tracking.” The introduction came at Lenovo Tech World 2024,…
Briefly: Hibbs Receives ASCIP Award; New Disney Film Stars Young Actress with CP
Featuring the Academy of Spinal Cord Injury Professionals and Disney+.
University of Pittsburgh’s Rachel Hibbs Receives ASCIP Excellence Award Rachel M. Hibbs, DPT, NCS, ATP, received the Excellence Award from the Therapy Leadership Council at the Academy of Spinal Cord Injury Professionals (ASCIP) annual conference. The award is given to a member “who has demonstrated outstanding qualities of leadership in the clinical application of SCI/D…
Briefly: Workshop to Investigate GLP-1R and Nervous System Disorders; ALS Survey Investigates AI Impact on AAC
Featuring the National Academies of Sciences, Engineering, and Medicine; and Boston Children’s Hospital.
NASEM Public Workshop to Discuss Applications of GLP-1R Agonists The National Academies of Sciences, Engineering, and Medicine (NASEM) is hosting a Sept. 10 day-long workshop to discuss the impact of glucagon-like peptide-r receptor (GLP-1R) agonists on central nervous system disorders, including neurodegenerative diseases such as Parkinson’s. The workshop will bring together experts from a number…